Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 1, 2009, Pages 91-102

  Berger, William E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Allergy & Asthma Associates of Southern California   (United States)

Author keywords

Allergic diseases; Azelastine; Pharmacokinetics; Rhinitis; Safety; Tolerability

Indexed keywords

ASTEPRO; AZELASTINE; NOSE SPRAY; PLACEBO; SORBITOL; SUCRALOSE; UNCLASSIFIED DRUG; ANTIHISTAMINIC AGENT; PHTHALAZINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; BITTER TASTE; BRONCHITIS; CHILD; CHRONIC DRUG ADMINISTRATION; CHRONIC RHINITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EPISTAXIS; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; NOSE CONGESTION; NOSE DISEASE; NOSE IRRITATION; NOSE SEPTUM PERFORATION; NOSE ULCER; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SNEEZING; SOMNOLENCE; SORE THROAT; THORAX DISEASE; UPPER RESPIRATORY TRACT INFECTION; VASOMOTOR RHINITIS; VIRUS INFECTION; XEROSTOMIA; AEROSOL; BIOAVAILABILITY; HAY FEVER; INTRANASAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

MEDA;

ADMINISTRATION, INTRANASAL; AEROSOLS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; HISTAMINE ANTAGONISTS; HUMANS; PHTHALAZINES; RHINITIS, ALLERGIC, SEASONAL; RHINITIS, VASOMOTOR; TREATMENT OUTCOME;

EID: 66449123627     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250802670474     Document Type: Review

References (45)

1. Bielory L, Ambrosio P. Conjunctivitis and allergic eye diseases. In: Kaliner MA, editor, Current Reviews of Rhinitis. Philadelphia, PA: Current Medicine, Inc; 2002:115-122
2. Wallace DV, Dykewicz MS, Bernstein DI, et al. Diagnosis and management of rhinitis: an updated practice parameter. Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 2008;122:S1-84 •• This comprehensive document contains complete guidelines for diagnosis and management of rhinitis developed by the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology.
3. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 2001;22:185-189
4. Lieberman P, Kaliner MA, Wheeler WJ. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Curr Med Res Opin 2005;21:611-8 • This open-label study evaluated the effectiveness of azelastine nasal spray in the treatment of symptoms of seasonal allergic rhinitis, mixed rhinitis and non-allergic vasomotor rhinitis as assessed by 2343 healthcare professionals. The authors report that 2 weeks of treatment with azelastine nasal spray controlled all rhinitis symptoms, including nasal congestion, regardless of rhinitis diagnosis.
5. Bernstein JA, Rezvani M. Mixed rhinitis: a new subclass of chronic rhinitis? second edition. In: Kaliner MA, editor, Current Reviews of Rhinitis, Philadelphia, PA: Current Medicine, Inc; 2006:69-78
6. Bernstein JA, Brandt D, Ratner P, Wheeler W. Assessment of a rhinitis questionnaire in a seasonal allergic rhinitis population. Ann Allerg Clin Immunol 2008;100:512-513
7. Lal D, Corey JP. Vasomotor rhinitis update. Curr Opin Otolaryngol Head Neck Surg 2004;12:243-247
8. Settipane RA. Nonallergic rhinitis. Current Review of Rhinitis. Philadelphia, PA: Current Medicine, Inc; 2002:53-65
9. Banov CH, Lieberman P. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol 2001;86:28-35 • The authors present two 3-week randomized studies in 426 subjects that demonstrate the safety and efficacy of azelastine nasal spray in patients with VMR.
10. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000;85:338-347
11. Reed SD, Lee TA, Mccrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004;22:345-361
12. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999;103:401-407
13. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108 (5 Suppl): S147-334
14. Azelastine® (azelastine hydrochloride) nasal spray. US full prescribing information. Meda Pharmaceuticals 2006. Available from: http://www.astelin.com/pdf/astelin-pi.pdf [Accessed October 9, 2008]
15. Bernstein JA. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy, and tolerability. Curr Med Res Opin 2007;23:2441-52 •• This literature search reviews all published data on azelastine hydrochloride between 1979 and 2007 and discusses the pharmacology, pharmacokinetics, clinical efficacy and tolerability of azelastine hydrochloride the treatment of SAR and VMR.
16. Zechel HJ, Brock N, Lenke D, Achterrath-Tuckermann U. Pharmacological and toxicological properties of azelastine, a novel antiallergic agent. Arzneimittelforschung 1981;31:1184-1193
17. Meda Pharmaceuticals, Somerset NJ, Data on file, 2007
18. Takao A, Shimoda T, Matsuse H, et al. Inhibitory effects of azelastine hydrochloride in alcohol-induced asthma. Ann Allergy Asthma Immunol 1999;82:390-394
19. Shin MH, Baroody F, Proud D, et al. The effect of azelastine on the early allergic response. Clin Exp Allergy 1992;22:289-295
20. Nieber K, Baumgarten C, Rathsack R, et al. Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin Exp Allergy 1993;23:69-71
21. Ito H, Nakamura Y, Takagi S, Sakai K. Effects of azelastine on the level of serum interleukin-4 and soluble CD23 antigen in the treatment of nasal allergy. Arzneimittelforschung 1998;48:1143-1147
22. Beck G, Mansur A, Afzal M. Effect of azelastine nasal spray on mediators of inflammation in patients with seasonal allergic rhinitis (SAR). American Academy of Allergy, Asthma, and Immunology 56th Annual Meeting. San Diego, CA; 2000
23. Ciprandi G, Cosentino C, Milanese M, Tosca MA. Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions. Ann Allergy Asthma Immunol 2003;90:434-438
24. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996;98:1088-1096
25. Busse W, Randlev B, Sedgwick J. The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol 1989;83:400-405
26. Umeki S. Effects of anti-allergic drugs on human neutrophil superoxide-generating NADPH oxidase. Biochem Pharmacol 1992;43:1109-1117
27. Morita M, Ohshima Y, Akutagawa H, et al. Inhibitory effects of azelastine hydrochloride on Ca2+ influx, actin polymerization and release of eosinophil cationic protein of an eosinophilic leukaemia cell line EoL-1. Curr Med Res Opin 1993;13:163-174
28. Nakamura T, Nishizawa Y, Sato T, Yamato C. Effect of azelastine on the intracellular Ca2+ mobilization in guinea pig peritoneal macrophages. Eur J Pharmacol 1988;148:35-41
29. Patel P, D'andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 2007;21:499-503
30. Pearlman DS, Grossman J, Meltzer EO. Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:258-262
31. Ratner PH, Findlay SR, Hampel F Jr, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol 1994;94:818-25 •• One of two initial double-blind, placebo-controlled studies supporting the efficacy and safety of 2 weeks of azelastine nasal spray in the treatment of 251 patients with seasonal allergic rhinitis.
32. Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J 1994;73:382-9 •• One of two initial double-blind, placebo-controlled studies supporting the efficacy and safety of 2 weeks of azelastine nasal spray in the treatment of 247 patients with seasonal allergic rhinitis.
33. Laforce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Azelastine NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 1996;76:181-8 • This study demonstrated broad clinical antirhinitis activity with the use of azelastine for 4 weeks in 264 patients with seasonal allergic rhinitis.
34. Lumry W, Prenner B, Corren J, Wheeler W. Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. Ann Allergy Asthma Immunol 2007;99:267-272
35. Berger WE, White MV. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 2003;91:205-211
36. Corren J, Storms W, Bernstein JA, et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 2005;27:543-553
37. Berger W, Hampel F Jr, Bernstein JA, et al. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:375-381
38. Weiler JM, Meltzer EO, Benson PM, et al. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol 1994;94:972-980
39. Meltzer EO, Weiler JM, Dockhorn RJ, et al. Azelastine nasal spray in the management of seasonal allergic rhinitis. Ann Allergy 1994;72:354-359
40. Allergies in America: a landmark survey of nasal allergy sufferers. Healthstar Communications, Inc. Sponsored by Altana Pharma US, Inc.; March 1, 2006
41. Physician survey sponsored by the American College of Allergy Asthma and Immunology. Rochester, NY: Harris Interactive Inc.; October 19-21, 2001
42. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-87
43. Berger WE, White MV. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 2003;91:205-211
44. Laforce CF, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 2004;93:154-159
45. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:74-81